Preclinical activity of sacituzumab govitecan (IMMU-132) in uterine and ovarian carcinosarcomas

作者：Salvatore Lopez, Emanuele Perrone, Stefania Bellone, Elena Bonazzoli, Burak Zeybek, Chanhee Han, Joan Tymon‐Rosario, Gary Altwerger, Gulden Menderes, Anna Bianchi, Luca Zammataro, Aránzazu Manzano, Paola Manara, Elena Ratner, Dan‐Arin Silasi, Gloria S. Huang, Masoud Azodi, Peter E. Schwartz, Francesco Raspagliesi, Roberto Angioli, Natália Buza, Pei Hui, Heather M. Bond, Alessandro D. Santin · 发表于：Oncotarget · 年份：2020 · DOI：10.18632/oncotarget.27342 · 被引用次数：53 · 研究领域：Uterine Myomas and Treatments、HER2/EGFR in Cancer Research、Gestational Trophoblastic Disease Studies

// Salvatore Lopez 1 , 2 , 3 , Emanuele Perrone 1 , Stefania Bellone 1 , Elena Bonazzoli 1 , Burak Zeybek 1 , Chanhee Han 1 , Joan Tymon-Rosario 1 , Gary Altwerger 1 , Gulden Menderes 1 , Anna Bianchi 1 , Luca Zammataro 1 , Aranzazu Manzano 1 , Paola Manara 1 , Elena Ratner 1 , Dan-Arin Silasi 1 , Gloria S. Huang 1 , Masoud Azodi 1 , Peter E. Schwartz 1 , Francesco Raspagliesi 3 , Roberto Angioli 4 , Natalia Buza 5 , Pei Hui 5 , Heather M. Bond 6 and Alessandro D. Santin 1 1 Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, CT, USA 2 Department of Experimental and Clinical Medicine, Magna Graecia University, Catanzaro, Italy 3 Department of Gynecologic Oncology, IRCCS National Cancer Institute, Milan, Italy 4 University Campus Bio Medico of Rome, Department of Obstetrics and Gynecology, Rome, Italy 5 Department of Pathology, Yale University School of Medicine, New Haven, CT, USA 6 Department of Clinical and Experimental Medicine, Laboratory of Molecular Haematopoiesis and Stem Cell Biology, University “Magna Græcia”, Catanzaro, Italy Correspondence to: Alessandro D. Santin, email: alessandro.santin@yale.edu Keywords: sacituzumab govitecan; IMMU-132; uterine carcinosarcoma; trop-2 Received: July 19, 2019 Accepted: October 26, 2019 Published: February 04, 2020 ABSTRACT Background Uterine and ovarian carcinosarcomas (CS) are rare cancers with poor prognosis. Sacituzumab-govitecan (SG) is a new class of antibody-drug-co...